AzTrials
AzTrials

Low Grade Serous Ovarian CarcinomaPhase 2ALEPRONCT05872204

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

A Phase 2 study testing Abemaciclib and Letrozole in people with Low Grade Serous Ovarian Carcinoma and Adult Type Granulosa Cell Tumor, run by Universitaire Ziekenhuizen KU Leuven at 12 sites in 3 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian cancer. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
Abemaciclib and Letrozole
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
12 sitesin 3 countries
Study dates
30 Nov 2023to Jan 2028
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  • Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.
  • Histological confirmation of diagnosis of low-grade serous (original diagnosis of low-grade serous carcinoma or original diagnosis of serous borderline tumor with subsequent diagnosis of low-grade serous carcinoma )or low-grade endometrioid carcinoma of ovary, fallopian tube or peritoneum or granulosa-cell tumor of the adult type and ER positivity on immunohistochemistry. In order to prevent inclusion of patients with high-grade serous carcinoma, diagnosis of low-grade serous carcinoma will be verified as part of screening review by a gynecologic pathologist. Tissue for confirmation can be from primary tumor or recurrence.
  • For Stage 1: only patients where platinum is still an option are eligible with no limitations in prior chemotherapy regimens and a maximum of 2 prior endocrine therapy regimens. For Stage 2: a further 20 patients where platinum is still an option will be included, with no limitations in prior chemotherapy regimens and a maximum of 2 prior endocrine therapy regimens. Fifteen patients where platinum is not an option are allowed with no limitations in prior chemotherapy regimens and maximum of 2 prior endocrine therapy regimens. Patients cannot have received chemotherapy for platinum resistant or refractory disease.
  • Age > 18 years at time of study entry.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
Show all 19Show fewer
  • Patient must have recurrent, measurable disease by RECIST v1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least 1 dimension (longest dimension to be recorded). Each lesion must be ≥10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam or must be ≥20 mm when measured by chest x-ray. Lymph nodes must be >15 mm in short axis when measured by CT or MRI.
  • Pre- and post-treatment tissue biopsy and ct-DNA blood sample are mandatory for translational studies. Tissue from an archival tissue sample or fresh tissue obtained from a core or excisional biopsy of a tumor lesion.
  • Patients who were previously treated with letrozole or another aromatase inhibitor are allowed, but capped at 10 patients in each cohort.
  • Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization.
  • Patients must not have remaining ovarian function. In women who have at least one retained ovary, menopause must be confirmed with laboratory confirmation. Women who have ovarian function are eligible but must be placed on hormonal suppression after a negative serum or urine human chorionic gonadotropin (hCG) test.
  • Abnormal organ function is permitted. However, patients must have:
  • absolute neutrophil count ≥1500/mL
  • platelets ≥100.000/mL
  • hemoglobin ≥9 g/dL
  • estimated creatinine clearance ≥ 45 ml/min as calculated using the method standard for the institution
  • total serum bilirubin ≤1.5 X ULN
  • aspartate aminotransferase (AST/SGOT) and/or alanine aminotransferase (ALT/SGPT) ≤3 X ULN
  • alkaline phosphatase ≤2.5x ULN (or ≤5.0x ULN if liver or bone metastases)

Who cannot join

  • For Stage 1: patients where platinum is not an option and platinum refractory patients are not allowed. For Stage 2: patients with platinum refractory disease are not allowed. Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy).
  • The patient has serious preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment (e.g. estimated creatinine clearance <30 mL/min), history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • Current use of food or drugs known to be potent CYP3A4 inhibitors, drugs known to be potent CYP3A4 inducers (for examples, see the Prohibited Concomitant Medications section).
  • Diagnosis of another malignancy within 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
  • Patient cannot have previously received a prior cyclin dependent kinase inhibitor (CDKi).
  • Known Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV) infection.
Show all 17Show fewer
  • Inability or unwillingness to swallow pills.
  • Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery).
  • Active infection requiring intravenous (IV) antibiotics or antifungals, or other uncontrolled recurrent illness requiring hospitalization.
  • History of any of the following: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), sudden cardiac arrest.
  • Prior hematopoietic stem cell or bone marrow transplantation.
  • Known history of brain metastasis(es) that may be considered active (screening imaging of brain is not required unless there is clinical suspicion of brain metastases). Patients with previously treated brain metastases may participate provided that the lesions are stable (without evidence of progression for at least 12 weeks on imaging), there is no evidence of new or enlarging brain metastases.
  • Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of goserelin (if applicable).
  • Known or possible hypersensitivity to letrozole or abemaciclib or any of their excipients.
  • Pre/perimenopausal women with a known hypersensitivity to gnRH (gonadotropin-releasing hormone) agonists.
  • Patients who are pregnant or breastfeeding.
  • Participation in an interventional Trial with an investigational medicinal product (IMP) or device. The patient has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomization, or is currently enrolled in any other type of medical research (for example: medical device) judged by the sponsor not to be scientifically or medically compatible with this study.

Trial locations and contacts

12 sites in 3 countries. Contact the study team or a site near you to ask about taking part.

Els Van Nieuwenhuysen, MD PhD contact

+3216342531

els.vannieuwenhuysen@uzleuven.be

Tine Ottenbourgs contact

+3216348131

tine.ottenbourgs@uzleuven.be

12 sites in 3 countries

France6 sites, 6 recruiting

  • Institut Bergonie

    Bordeaux, Gironde, 33000

    Coriolan Lebreton, MD, c.lebreton@bordeaux.unicancer.fr

    Coriolon Lebreton, MD

    Recruiting

  • Centre Leon Berard

    Lyon, Métropole de Lyon, 69008

    Isabelle Ray-Coquard, MD PhD, isabelle.ray-coquard@lyon.unicancer.fr

    Isabelle Ray-Coquard, MD PhD

    Recruiting

  • Groupe Hospitalier Diaconesses Croix Saint Simon

    Paris, Île-de-France Region, 75020

    Frédéric Selle, MD, fselle@hopital-dcss.org

    Frédéric Selle, MD

    Recruiting

  • Institut De Cancerologie De L'Ouest

    Saint-Herblain, Loire-Atlantique, 44800

    Dominique Berton, MD, Dominique.berton@ico.unicancer.fr

    Dominique Berton, MD

    Recruiting

  • Institut De Cancerologie Strasbourg Europe

    Strasbourg, Bas-Rhin, 67200

    Lauriane Eberst, MD, l.eberst@icans.eu

    Lauriane Eberst, MD

    Recruiting

  • Institut Universitaire Du Cancer Toulouse-Oncopole

    Toulouse, Haute-Garonne, 31059

    Laurence Gladieff, MD, gladieff.laurence@iuct-oncopole.fr

    Laurence Gladieff, MD

    Recruiting

Other trials in France

Belgium3 sites, 3 recruiting

  • UZ Gent

    Ghent, Oost-Vlaanderen, 9000

    Hannelore Denys, MD PhD, +3293322692, hannelore.denys@uzgent.be

    Hannelore Denys, MD PhD

    Recruiting

  • UZ Leuven

    Leuven, Vlaams-Brabant, 3000

    Els Van Nieuwenhuysen, MD PhD, +3216342531, els.vannieuwenhuysen@uzleuven.be

    Tine Ottenbourgs, +3216348131, tine.ottenbourgs@uzleuven.be

    Recruiting

  • CHU de Liège

    Liège, Liège, 4000

    Frédéric Kridelka, MD, +3243237169, Frederic.Kridelka@chuliege.be

    Frédéric Kridelka, MD

    Recruiting

Other trials in Belgium

Netherlands3 sites, 3 recruiting

  • University Medical Center Groningen

    Groningen, Provincie Groningen, 9713 GZ

    Hilde Jalving, MD, m.jalving@umcg.nl

    Hilde Jalving, MD

    Not yet recruiting

  • Erasmus Medical Center Rotterdam

    Rotterdam, South Holland, 3015 GD

    Ingrid Boere, MD, i.boere@erasmusmc.nl

    Ingrid Boere, MD

    Recruiting

  • University Medical Center Utrecht

    Utrecht, Utrecht, 3584 CX

    Inge Baas, MD, I.O.Baas-3@umcutrecht.nl

    Inge Baas, MD

    Not yet recruiting

Other trials in Netherlands

About this study

Official title: A Phase II, Open-label, Multicenter Study of Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian cancer.

Read the detailed description

Patients with recurrent, persistent and/or metastatic estrogen receptor-positive rare ovarian cancer, who failed one line of platinum based chemotherapy for advanced or recurrent disease, will be included in this study. One cohort will include low-grade serous or endometrioid epithelial ovarian cancer and another cohort will include adult type granulosa cell tumors. The results of large randomized phase 3 trials of the combination of an aromatase inhibitor combined with a CDK4/6 inhibitor in hormone sensitive, HER2 negative breast cancer can form the basis for a trial with this drug combination in hormone sensitive rare ovarian cancer. The aim is to increase the response rate to aromatase inhibitors and the duration of response in this study population with limited therapeutic options, monitor the quality of life and explore the (epi)genomic signatures that correlate with response or endocrine resistance. Abemaciclib will be supplied as capsules administered orally, 150 mg every 12 hours (Q12H) on Days 1 to 28 of a 28-day cycle, plus letrozole 2.5 mg OD Days 1 to 28 of a 28-day cycle.

Being tested
Abemaciclib, Letrozole

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AbemaciclibDrug

    Also called Verzenios

    150 mg tablet twice daily

  • LetrozoleDrug

    Also called Femara

    2.5 mg tablet once daily

Study groups in NCT05872204
Study groupRoleWhat they receive
Abemaciclib and letrozoleExperimentalParticipants received abemaciclib 150 mg tablet orally twice daily and letrozole tablet 2.5 mg orally once daily until disease progression, unacceptable adverse event(s) or death.
Receives: Drug: Abemaciclib; Drug: Letrozole

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The overall response rate (ORR) of the combination of abemaciclib and letrozole, according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    RECIST is a standard system to measure how cancer responds to different treatments, including chemotherapy, immunotherapy, and radiation therapy.

    Measured: Week 24

  2. The overall response rate (ORR) of the combination of abemaciclib and letrozole, according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    RECIST is a standard system to measure how cancer responds to different treatments, including chemotherapy, immunotherapy, and radiation therapy.

    Measured: 3 years

Secondary outcomes (7)

  1. The duration of response (DOR) of the combination of abemaciclib and letrozole in the intention-to-treat (ITT) population at Week 24 and 3 years.

    The DOR is defined as the time from response until disease progression or death in patients who achieve complete or partial response.

    Measured: Week 24 and 3 years

  2. The clinical benefit rate (CBR) of the combination of abemaciclib and letrozole.

    The CBR is defined as the proportion of patients with a confirmed complete response (CR), partial response (PR) and stable disease (SD) maintained for at least 24 weeks.

    Measured: Week 24 and 3 years

  3. The incidence and severity of adverse events, with severity determined according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0).

    Based on clinically relevant changes from baseline for vital signs and laboratory findings. CTCAE v5.0 uses a range of grades from 1 to 5:

    Grade 1 = mild Grade 2 = moderate Grade 3 = severe Grade 4 = life-threatening Grade 5 = death

    Measured: 3 years

  4. Progression-free survival (PFS).

    PFS is defined as the time from start of treatment until disease progression/relapse or death from any cause. If the specific event (disease progression/relapse, death, whatever comes first) does not occur, PFS will be censored at the date of last tumor assessment. In case no tumor assessment is available, patients will conservatively be censored at the date of first letrozole + abemaciclib dose.

    Measured: 3 years

  5. Overall survival (OS).

    OS is defined as the time from start of treatment until death from any cause. Patients who are still alive at the time of OS analysis will be censored at the last date they were known to be alive.

    Measured: 3 years

  6. Change from baseline in health-related quality of life using the EQ-5D-5L questionnaire.

    The EuroQol Five-Dimension Five-Level Questionnaire (EQ-5D-5L) is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Measured: Baseline and 3 years

  7. Change from baseline in health-related quality of life using the EORTC QLQ-C30 questionnaire.

    The EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions. The questionnaire is composed of multi-item scales and single items.

    Measured: Baseline and 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 May 2023
  2. Study start30 Nov 2023
  3. Primary completionJan 2028 (estimated)
  4. Study completionJan 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05872204
Sponsor's protocol ID
S66468
Acronym
ALEPRO
Status last verified
Apr 2026
First submitted
2 May 2023
Last updated
5 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ottenbourgs T, van Gorp T, Kridelka F, Baert T, Denys H, Selle F, Baas I, Van Rompuy AS, Lambrechts D, Van Nieuwenhuysen E. A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial. Int J Gynecol Cancer. 2024 Apr 1;34(4):627-630. doi: 10.1136/ijgc-2023-005189.

    PubMed 38453176

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Abemaciclib and Letrozole in people with Low Grade Serous Ovarian Carcinoma and Adult Type Granulosa Cell Tumor, run by Universitaire Ziekenhuizen KU Leuven at 12 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 19 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in France, Belgium, Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Els Van Nieuwenhuysen, MD PhD (+3216342531, els.vannieuwenhuysen@uzleuven.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The overall response rate (ORR) of the combination of abemaciclib and letrozole, according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (time frame: Week 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05872204, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in